NEWS & EVENTS

ATEM Capital LLC provides this Privacy Policy (collectively with its affiliates and the funds and accounts sponsored or managed by them, “ATEM,” “we,” “us,” or “our”). It is intended to describe the personal data or personal information (collectively, “Personal Information”) we collect, how we use and share it, and rights you may have regarding this information. By accessing the website, you agree to our collection and use of Personal Information as described in this Policy and our Terms of Use.

Triumvira Immunologics, an ATEM Capital portfolio company, announced positive initial clinical data from the ongoing Phase 1/2 trial of its lead drug candidate. Initial clinical data demonstrate TAC01-HER2 was well-tolerated in both dosing cohorts and early signals of clinical activity were observed in the higher of the two dosing cohorts, demonstrating a 75% disease control rate, including one partial response. Triumvira is on track to complete enrollment of the Phase 1 portion of the study by the end of 2022, identify the optimal dose and initiate the Phase 2 registration component of the trial in the first quarter of 2023.

ATEM Capital joined Builders VC, Khosla Ventures, TechU Ventures, FundersClub, and other reputable investors in Arpeggio's $17M Series A raise. Arpeggio is developing an innovative drug discovery platform that reconstructs the complex biological cascades affected by the molecule and compares the effects with diseases for which the new molecular compound may have therapeutic value. New capital will support ongoing development of their drug pipeline targeting transcriptional mechanisms in disease.

Amolyt Pharma announced that the company has been selected for the French Tech FT120, a support program for French late-stage startups by the French State. The French Tech 120 program identifies the 120 top-performing startups based in France. This year’s award included 7 biotechnology companies developing innovative therapies. The selection is based on financial criteria of fundraising or hypergrowth of sales. The globally renowned reputation of the French Tech 120 program will greatly benefit the company by providing increased visibility and a range of services.

Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that do not require gene editing and co-opt the natural biology of T cells to treat patients with solid tumors, today announced the presentation of preclinical data from its proof-of-concept study in gastric cancer. These new data demonstrate that Triumvira’s novel T cell antigen coupler (TAC)-T cell candidate targeting Claudin 18.2 (CLDN18.2) effectively eradicates CLDN18.2-expressing gastric tumor cells in vitro and in vivo.

Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, announced positive results from its Phase 1 clinical trial of AZP-3601, a potential treatment for hypoparathyroidism, at the American Society for Bone and Mineral Research 2021 Annual Meeting. These findings showed that repeated injection of AZP-3601 to healthy volunteers resulted in a fast, dose-dependent increase in serum calcium levels that sustained throughout the treatment period. Furthermore, due to the unique mechanism of action of AZP-3601 and its short pharmacokinetic half-life, no increase in urine calcium excretion was detected, and bone biomarkers were unchanged.

Triumvira Immunologics announced that the first patient has been dosed as part of the TACTIC-2 trial evaluating the company’s lead candidate, TAC01-HER2, an autologous T cell therapy for the treatment of human epidermal growth factor receptor 2 (HER2) positive solid tumors. “The initiation of our TACTIC-2 trial represents a significant milestone for Triumvira and an opportunity to establish clinical proof of concept for our TAC technology. We look forward to sharing our progress with this program as we build out a pipeline of candidates targeting solid tumors," said Paul Lammers, M.D., M.Sc., President and CEO of Triumvira.

Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, announced that the company had closed an $80 million Series B equity financing round. The financing was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital and all investors from the company’s July 2019 Series A financing, including LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation. The funds will be used to continue clinical development of AZP-3601 for hypoparathyroidism while progressing AZP-3813 through IND-enabling activities in acromegaly and further expanding early-stage pipeline.

Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, announced that the company had closed an $80 million Series B equity financing round. The financing was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital and all investors from the company’s July 2019 Series A financing, including LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation. The funds will be used to continue clinical development of AZP-3601 for hypoparathyroidism while progressing AZP-3813 through IND-enabling activities in acromegaly and further expanding early-stage pipeline.